Loading stock data…
$7.68-0.07 (-0.90%)
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.00M↓ | $19.64M↑ | $859,000↓ | $12.34M↑ | $3.85M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.62M↓ | -$17.28M↑ | -$48.03M↓ | -$8.46M↑ | -$12.86M |
| Net Income | -$20.19M↓ | -$16.63M↑ | -$48.07M↓ | -$8.29M↑ | -$12.88M |
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include A...